NCT01820546

Brief Summary

In multiple myeloma "cancer stem" cells can be defined and quantified with flow cytometry. More, these cells can be related to treatment response.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
96

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 26, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 28, 2013

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
Last Updated

January 6, 2016

Status Verified

January 1, 2016

Enrollment Period

3 years

First QC Date

March 26, 2013

Last Update Submit

January 4, 2016

Conditions

Multiple Myeloma

Outcome Measures

Primary Outcomes (1)

  • Treatment Response

    After 3 courses chemotherapy treatment response

    3 months

Secondary Outcomes (1)

  • Treatment Response

    6 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

New Diagnosed or Relapsed Multiple Myeloma Patients

You may qualify if:

  • New Diagnosed or Relapsed Multiple Myeloma
  • Routine Bone Marrow Aspiration will be done

You may not qualify if:

  • Bone Marrow Aspiration is not Needed

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara University Hematology Unit

Ankara, 06590, Turkey (Türkiye)

Location

Related Publications (1)

  • Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood. 2004 Mar 15;103(6):2332-6. doi: 10.1182/blood-2003-09-3064. Epub 2003 Nov 20.

    PMID: 14630803BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Bone Marrow

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Mehmet Ozen, MD

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 26, 2013

First Posted

March 28, 2013

Study Start

January 1, 2013

Primary Completion

January 1, 2016

Study Completion

January 1, 2016

Last Updated

January 6, 2016

Record last verified: 2016-01

Locations

TU(1)